QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023
23. Januar 2023 08:30 ET
|
QSAM Biosciences Inc.
QSAM invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Austin, TX, Jan. 23, 2023...
QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®
13. Juli 2022 13:32 ET
|
QSAM Biosciences, Inc.
AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- via Investorwire -- QSAM Biosciences Inc. (OTCQB: QSAM) (the “Company”), a company developing next-generation targeted therapeutic...
QSAM Biosciences Doses First Patient in its Clinical Trial for Cyclosam®, Radiopharmaceutical Drug Candidate for the Treatment of Bone Cancer
28. April 2022 07:00 ET
|
QSAM Biosciences Inc.
Austin, TX, April 28, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma
02. Februar 2022 08:30 ET
|
QSAM Biosciences Inc.
Austin, TX, Feb. 02, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Receives Orphan Drug Designation from FDA for CycloSam® in the Treatment of Osteosarcoma
18. August 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Aug. 18, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment...
QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy
17. März 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the...
QSAM Biosciences Appoints Charles J. Link, Jr., M.D., Experienced Biotech Executive and Innovator, to Board of Directors
16. Februar 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Feb. 16, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced...
QSAM Biosciences Receives Favorable Safety Results in Study for its Leading Radiopharmaceutical Drug Candidate
21. Januar 2021 09:00 ET
|
QSAM Biosciences Inc.
Palm Beach, FL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines for the treatment of cancer and related diseases and...
QSAM Biosciences Starts Trading under New Symbol: QSAM
09. Oktober 2020 09:00 ET
|
QSAM Biosciences Inc.
Palm Beach, FL, Oct. 09, 2020 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) announced today that it has commenced trading on The OTC Markets under the new stock symbol QSAM. The company’s...